Genetic subpopulations of rift valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13566-13575

  Lokugamage, Nandadeva ^a   Freiberg, Alexander N ^a,b   Morrill, John C ^a,b   Ikegami, Tetsuro ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; NUCLEOTIDE; VIRUS VACCINE;

ARTICLE; ATTENUATION; CONTROLLED STUDY; GENE MUTATION; GENETIC RISK; GENETIC STABILITY; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL; REVERTANT; RIFT VALLEY FEVER BUNYAVIRUS; RISK ASSESSMENT; VIRAL GENETICS; VIRULENCE; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CELL LINE; CRICETINAE; GENES, VIRAL; MUTATION; POLYMERASE CHAIN REACTION; RECOMBINATION, GENETIC; RIFT VALLEY FEVER VIRUS;

RIFT VALLEY FEVER VIRUS;

EID: 84870660408     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02081-12     Document Type: Article

References (35)

1. Bass BL. 2002. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 71:817- 846.
2. Battles JK, Dalrymple JM. 1988. Genetic variation among geographic isolates of Rift Valley fever virus. Am. J. Trop. Med. Hyg. 39:617- 631.
3. Billecocq A, et al. 2008. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 378:377-384.
4. Bird BH, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST. 2007. Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J. Virol. 81:2805-2816.
5. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. 2009. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234:883- 893.
6. Caplen H, Peters CJ, Bishop DH. 1985. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66:2271-2277.
7. Crabtree MB, et al. 2012. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Negl. Trop. Dis. 6:e1639. doi:10.1371/journal.pntd.0001639.
8. Daubney R, Hudson JR. 1931. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep cattle and man from east Africa. J. Pathol. Bacteriol. 34:545-579.
9. Engdahl C, Naslund J, Lindgren L, Ahlm C, Bucht G. 2012. The Rift Valley fever virus protein NSm and putative cellular protein interactions. Virol. J. 9:139.
10. Grobbelaar AA, et al. 2011. Molecular epidemiology of Rift Valley fever virus. Emerg. Infect. Dis. 17:2270 -2276.
11. Ikegami T, Makino S. 2011. The pathogenesis of Rift Valley fever. Viruses 3:493-519.
12. Ikegami T, Makino S. 2009. Rift Valley fever vaccines. Vaccine 27(Suppl 4):D69-D72.
13. Ikegami T, et al. 2009. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog. 5:e1000287. doi:10.1371/journal.ppat.1000287.
14. Ikegami T, Won S, Peters CJ, Makino S. 2006. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J. Virol. 80:2933-2940.
15. Ito N, et al. 2003. Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol. Immunol. 47:613-617.
16. Kark JD, Aynor Y, Peters CJ. 1985. A Rift Valley fever vaccine trial. 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection. Vaccine 3:117-122.
17. Keegan K, Collett MS. 1986. Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J. Virol. 58:263-270.
18. Keegan LP, Leroy A, Sproul D, O'Connell MA. 2004. Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes. Genome Biol.5:209. doi:10.1186/gb-2004-5-2-209.
19. Le May N, et al. 2004. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116:541-550.
20. Le May N, et al. 2008. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 4:e13. doi:10.1371/journal.ppat.0040013.
21. Linthicum KJ, Davies FG, Kairo A, Bailey CL. 1985. Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya. J. Hyg. (Lond.) 95:197-209.
22. Mandell RB, Flick R. 2011. Rift Valley fever virus: a real bioterror threat. J. Bioterror. Biodef. 2:108. doi:10.4172/2157-2526.1000108.
23. Mandell RB, Flick R. 2010. Rift Valley fever virus: an unrecognized emerging threat? Hum. Vaccin. 6:597- 601.
24. Meegan JM. 1979. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizootic and virological studies. Trans. R. Soc. Trop. Med. Hyg. 73:618-623.
25. Morrill JC, et al. 1991. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 9:35- 41.
26. Morrill JC, et al. 1987. Pathogenicity and immunogenicity of a mutagenattenuated Rift Valley fever virus immunogen in pregnant ewes. Am. J.Vet. Res. 48:1042-1047.
27. Morrill JC, Mebus CA, Peters CJ. 1997. Safety and efficacy of a mutagenattenuated Rift Valley fever virus vaccine in cattle. Am. J. Vet. Res. 58:1104-1109.
28. Morrill JC, Mebus CA, Peters CJ. 1997. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am. J. Vet. Res.58:1110 -1114.
29. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. 2010. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 41:61.
30. Pittman PR, et al. 1999. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18:181-189.
31. Saluzzo JF, Smith JF. 1990. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 8:369 -375.
32. Schmaljohn C, Nichol ST. 2007. Bunyaviridae, p 1741-1789. In Knipe DM, et al. (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
33. Swanepoel R, Coetzer JAW. 2004. Rift Valley fever, p 1037-1070. In Coetzer JAW, et al. (ed), Infectious diseases of livestock with special reference to southern Africa, 2nd ed. Oxford University Press, Cape Town, South Africa.
34. Vialat P, Muller R, Vu TH, Prehaud C, Bouloy M. 1997. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res. 52:43-50.
35. Won S, Ikegami T, Peters CJ, Makino S. 2007. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81: 13335-13345.